Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the long-term safety of repeat daily doses of pazopanib in cancer subjects with solid tumors

Outcome Description:

To evaluate the safety assessments; adverse events, vital signs, physical examinations, electrocardiograms, multi-gated acquisition scans or echocardiograms (only for patients on pazopanib and lapatinib combination therapy), and clinical laboratory assessments.

Outcome Time Frame:

Subjects will stay on the study as long as they are benefiting from treatment, have not met one of the stopping criteria, or experienced a toxicity up to 72 months.

Safety Issue:

No

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United States: Food and Drug Administration

Study ID:

VEG105430

NCT ID:

NCT00387205

Start Date:

May 2006

Completion Date:

June 2012

Related Keywords:

• Cancer
• Pazopanib
• monotherapy and combination therapies
• cancer
• malignant tumor
• safety
• chronic administration
• lapatinib (TYKERB, TYVERB)
• solid
• GW786034